Phase I Study of Mosperafenib, a Novel Paradox Breaker B-Raf Proto-Oncogene Serine/Threonine Kinase (BRAF) Inhibitor, in Patients With BRAF V600-Mutant Solid Tumors.

Journal:

Journal of Clinical Oncology

Published:

2026-03-28

DOI:

10.1200/jco-25-02444

Affiliations:

19

Authors:

27

Go to article

Institutions	Authors	Share
Roche, Switzerland	15.000000 15.000000	0.56
Antwerp University Hospital (UZA), UA, Belgium	1.000000	0.04
University Hospitals Leuven (UZ Leuven), Belgium	1.000000	0.04
University Hospital Zurich (UHZ), Switzerland	1.000000	0.04
START Madrid-CIOCC, Spain	1.000000	0.04
Sarah Cannon Research Institute - UK, United Kingdom (UK)	1.000000	0.04
Hospital Universitario de Navarra (HUN), Spain	1.000000	0.04
Roche Products Limited, United Kingdom (UK)	1.000000	0.04
Hammersmith Hospital, Imperial College Healthcare NHS Trust, United Kingdom (UK)	0.500000	0.02
Herlev University Hospital, Denmark	0.500000	0.02
Gentofte University Hospital, Denmark	0.500000	0.02
University of Eastern Piedmont "Amedeo Avogadro" (UPO), Italy	0.500000	0.02
Newcastle University, United Kingdom (UK)	0.500000	0.02
The Newcastle Upon Tyne Hospitals NHS Foundation Trust (NUTH), United Kingdom (UK)	0.500000	0.02
New Zealand Clinical Research, New Zealand	0.500000	0.02
Auckland City Hospital (ACH), New Zealand	0.500000	0.02
Vall d'Hebron University Hospital (HUVH), ICS, Spain	0.500000	0.02
Autonomous University of Barcelona (UAB), Spain	0.500000	0.02

Interested in Oncology and Carcinogenesis?